Vectura Group plc

Vectura provides formulation, device, and development services to help customers bring inhaled medicines to market.

With expertise in powder and liquid formulations, as well as a portfolio of proprietary device and formulation technologies, Vectura can support programs for small molecules, biologics, or complex combinations.

Customers can access the delivery technology best suited to the needs of their development program, including unit-dose and multi-unit dose DPIs, pMDIs, and smart nebulisers, suitable for home or hospital applications.

With extensive analytical testing facilities, Vectura can undertake the comprehensive array of test methodologies and physical properties characterisation required for inhaled products, in addition to stability studies and device verification testing.

Vectura also offers seamless scale-up from laboratory to pilot to commercially-representative scale as well as GMP drug product and device manufacturing for clinical trials.

With more than 20 years’ experience, the company’s track record of success offers customers confidence in Vectura as a trusted development partner for their inhaled product candidate. Being able to provide customers with a single partner from early development to late-phase clinical trials and beyond offers benefits in terms of continuity, shortened timelines, and reduced costs.

Articles

Vectura helps customers bring inhaled medicines to market with a combination of formulation science, device technology, and inhaled product development expertise.  

Vectura – Helping You Succeed with Inhaled Product Development

http://www.pharmtech.com/pt_w/key_considerations


	Dry powder inhalers are an important technology for the delivery of therapies for both respiratory and non-respiratory disease areas. The development of such drug-device combination products is highly complex and several factors can have a significant impact on the success of the program. This webcast discusses the key considerations to reduce risk when developing a DPI product from early clinical trials through to scale-up, and provides insights for both novel and generic development programs.

		Understanding different options for dry powder inhaler technology

		Key considerations for DPI product development

		Manufacturing strategies for seamless transition and scalability from lab to commercial scale

		Relevant regulatory guidance and risk-based approaches to process development and device design 

		Device strategies for novel and generic inhaled development programs

Andreas Meliniotis, Director, Device Development, Vectura Group plc.

Wednesday, Jun. 24, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

	On demand available after final airing Jun. 24, 2021

Webcasts

Dry powder inhalers (DPIs) are an important delivery technology for inhaled medicines in both respiratory and non-respiratory disease areas. Andreas Meliniotis, director of device development at Vectura, helps navigate the complex area of DPI product development and highlights the key considerations for both novel- and generic-drug programs.

Live: Wednesday, Jun. 24, 2020 at 11am EDT |8am PDT |4pm BST |5pm CEST

On demand available after final airing Jun. 24, 2021

Register free